Catherine Ramsey Schulte

Illumina, Inc. (NASDAQ: ILMN) announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock.  The Illumina Analysts: Baird analyst Catherine Ramsey Schulte maintained a Neutral rating on Illumina shares and lowered...

EXACT Sciences Corporation (NASDAQ: EXAS) shares have been on a heady run this year. Despite the sell side's optimism on the company's fundamentals, analysts have become wary of Exact's astronomical valuation, with the company holding its highest valuation since the summer of...

Analysts at Baird turned bullish on Illumina, Inc. (NASDAQ: ILMN) in reaction to the company's third-quarter earnings report in which revenue grew at its fastest pace since the fourth quarter of 2015. Analyst Catherine Ramsey Schulte upgraded Illumina's stock from Neutral to Outperform with...